RepliCel is a regenerative medicine company focused on developing autologous that address diseases caused by a deficit of healthy cells required for normal healing and function. The company’s RCT-01, RCS-01, and cell therapies are designed to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness. has an exclusive license for in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications.  The Company’s product pipeline is comprised of multiple anticipated to launch through 2015, in addition to Shiseido’s own clinical trial of and the device in late prototype development. Please visit for additional information.



Enjoy this site? Please spread the word :)